10x Genomics (TXG) Income from Continuing Operations (2018 - 2026)

10x Genomics has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 13470000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 13470000.0, up 60.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 22656000.0 (up 85.57% YoY), and the FY2025 annual result was 43544000.0, up 76.16% from the prior year.
• Income from Continuing Operations came in at 13470000.0 for Q1 2026 at 10x Genomics, up from 16252000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 34538000.0 in Q2 2025 to a low of 92986000.0 in Q3 2023.
• The 5-year median for Income from Continuing Operations is 41914000.0 (2022), against an average of 38867058.82.
• Across the five-year window, Income from Continuing Operations sank 483.22% in 2022 and surged 191.14% in 2025, its largest moves.
• 10x Genomics' Income from Continuing Operations stood at 17215000.0 in 2022, then tumbled by 184.36% to 48952000.0 in 2023, then dropped by 0.16% to 49028000.0 in 2024, then surged by 66.85% to 16252000.0 in 2025, then rose by 17.12% to 13470000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 13470000.0 (Q1 2026), 16252000.0 (Q4 2025), and 27472000.0 (Q3 2025), per Business Quant data.